Qingdao Yingkang Medical Investment Co., Ltd. agreed to acquire Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million on August 6, 2021. The price of this equity transfer was based on the evaluation results and negotiated by both parties to the transaction. The price of the creditor’s rights transfer is the sum of the principal of the loan under the "Loan Contract" that the company has on Hangzhou Yikang (the upper limit of the loan is CNY 82 million. The specific amount is based on the actual loan amount as of the date of payment of the consideration for this transaction) and the corresponding amount of all the corresponding interest incurred according to the "Loan Contract" (calculated until the payment date of the creditor’s rights transfer consideration). As of August 30, 2021, INKON Life Technology Co., Ltd. shareholders approved the transaction in special shareholders’ meeting. Qingdao Yingkang Medical Investment Co., Ltd. completed the acquisition of Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) on September 10, 2021.